Clinical Trials Network

Study

Current Status

Objectives of the study

SW CTN Role

CTN-0080: MOMs

Implementation

To evaluate the impact of treating opioid use disorder in pregnant women with BUP-XR, compared to BUP-SL, on maternal-infant outcomes. 

Study site

CTN-0096: MOUDX

Phase 1

To develop and test a culturally-centered program to support the integration of medications (BUP, XR-naltrexone) to treat OUD among AI/AN in primary care and addiction treatment clinics.

Lead node

CTN-0099: ED-INNOVATION

Pre-implementation

To evaluate implementation of emergency department (ED)-initiated BUP in a large number of sites; compare extended release (XR)-BUP with sublingual (SL) BUP in ED patients with untreated OUD; and track treatment follow-up outside of the ED.

2 study sites

CTN-0100: RDD

Site selection

To 1) test strategies to improve MOUD treatment retention and improve outcomes among patients who have been successfully stabilized on MOUD and want to stop MOUD; and 2) identify predictors of successful outcome and develop a stage model of relapse risk.

Site survey submitted

CTN-0102: Rural MOUD

Site selection

To 1) test expanded treatment access to improve retention on MOUD in highly impacted rural areas, 2) evaluate comparative effectiveness between office-base opioid treatment (OBOT) vs OBOT + telemedicine (TM) in 30 sites.

Site survey submitted

Other Currently Active CTN Studies

Study

Current Status

Objectives of the study

CTN-0098: EXHIT-ENTRE

Site selection

This study will examine whether 1) in hospitals with addiction medicine consultation services, hospital-initiated extended release buprenorphine (XR-BUP), compared to other OUD medications, results in increased OUD treatment engagement following hospital discharge; and 2) training hospitals without such consultation services on best practices for initiating OUD medication using consultation service hubs improves medication uptake in hospitals and following discharge.

CTN-0101: STOP

Site selection

This study will test the efficacy of a primary care Subthreshold Opioid Use Disorder Prevention (STOP) intervention to reduce unhealthy opioid use and examine the impact of STOP on progression to moderate-severe OUD, overdose risk behavior, and overdose events in adults with unhealthy use of illicit/prescribed opioids.

Upcoming Studies

Study

Current Status

Objectives of the study

CTN-0103

Protocol development

To expand clinical research training in evidence-based quality improvement methods.  Participating primary care practices will be trained in the 1) use of a study-developed toolkit of research and evaluation quality improvement methods intended to expand provider knowledge and performance in the delivery of evidence-based MOUD, 2) systematic tracking of standardized outcome metrics, and 3) sharing of standardized data with other LC members, so that practices can use this empirical information to refine their care model over time. 

CTN-0104

Protocol development

To address stigma around treating OUD by conducting a national provider survey of the general practice workforce. Specific aims are: (1) to define the scope of provider stigma and identify barriers to treating opioid use disorders in medical care and dental care settings, and (2) to investigate what potential intervention strategies are needed to address identified barriers to improve the delivery of opioid treatment in primary care settings across the United States.

CTN-0105

Protocol development

To use mixed methods to study pharmacists’ knowledge of, attitudes about, and intention to provide patient care and services for Screening for substance use, Brief Intervention, and Referral to Treatment (SBIRT) for Substance Use Disorders (SUDs) and Medication treatment for Opioid Use Disorders (MOUD). The findings will inform barriers and facilitators related to pharmacist-provided services and patient care for SBIRT and MOUD.

CTN-0106

Protocol development

To conduct a series of analyses with data from the Brief Addiction Monitor (BAM), which has been selected for a national MBC initiative within the Veteran’s Administration. The goal of the work will be to derive and validate two new scales from the BAM. One scale is intended for use in Opioid Use Disorder (OUD) specialty care programs. The second version is intended for use in primary care based MOUD.

CTN-0107

Protocol development

A 3-site, randomized controlled trial using Peer Recovery Coaches trained in FORCE (FAVOR Overdose Recovery Coaching Evaluation), who will engage with opioid overdose survivors in the emergency department to get permission to contact them and engage participants in care and develop a patient-centered recovery plan. The FORCE intervention will be tailored to the participant's needs and will continue for 12 months after enrollment. This intervention will be compared to Treatment as Usual (TAU) in which overdose survivors receive referral to treatment. Outcomes include engagement in formal OUD treatment between groups, retention in treatment, and number of overdoses after enrollment.